SELLAS Life Sciences Group, Inc. (NASDAQ:SLS) Short Interest Down 14.9% in January

SELLAS Life Sciences Group, Inc. (NASDAQ:SLS) saw a significant decrease in short interest during the month of January. As of January 15th, there was short interest totaling 42,044,430 shares, a decrease of 14.9% from the December 31st total of 49,429,420 shares. Based on an average trading volume of 16,240,884 shares, the days-to-cover ratio is presently 2.6 days. Approximately 29.9% of the shares of the company are sold short. Approximately 29.9% of the shares of the company are sold short. Based on an average trading volume of 16,240,884 shares, the days-to-cover ratio is presently 2.6 days.

Wall Street Analyst Weigh In

Separately, Weiss Ratings reissued a “sell (d-)” rating on shares of SELLAS Life Sciences Group in a report on Thursday, January 22nd. One research analyst has rated the stock with a Buy rating and one has issued a Sell rating to the stock. According to MarketBeat, the stock has a consensus rating of “Hold” and a consensus target price of $7.00.

Insiders Place Their Bets

In other SELLAS Life Sciences Group news, Director Katherine Bach Kalin purchased 63,400 shares of SELLAS Life Sciences Group stock in a transaction dated Wednesday, November 19th. The stock was purchased at an average price of $1.59 per share, with a total value of $100,806.00. Following the transaction, the director directly owned 104,400 shares of the company’s stock, valued at $165,996. This trade represents a 154.63% increase in their ownership of the stock. The purchase was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link. Corporate insiders own 1.20% of the company’s stock.

Institutional Inflows and Outflows

Several large investors have recently modified their holdings of the business. Blair William & Co. IL purchased a new stake in shares of SELLAS Life Sciences Group in the second quarter worth approximately $35,000. Simon Quick Advisors LLC bought a new position in SELLAS Life Sciences Group in the 2nd quarter valued at $44,000. ProShare Advisors LLC bought a new position in SELLAS Life Sciences Group in the 2nd quarter valued at $43,000. Geode Capital Management LLC increased its stake in SELLAS Life Sciences Group by 168.2% in the second quarter. Geode Capital Management LLC now owns 2,200,428 shares of the company’s stock worth $4,819,000 after purchasing an additional 1,379,988 shares during the period. Finally, Police & Firemen s Retirement System of New Jersey bought a new stake in shares of SELLAS Life Sciences Group during the second quarter worth $51,000. Hedge funds and other institutional investors own 17.38% of the company’s stock.

SELLAS Life Sciences Group Stock Performance

NASDAQ:SLS opened at $4.16 on Wednesday. The firm has a market capitalization of $592.55 million, a PE ratio of -14.86 and a beta of 2.27. The stock’s fifty day moving average is $3.13 and its 200 day moving average is $2.24. SELLAS Life Sciences Group has a fifty-two week low of $0.95 and a fifty-two week high of $5.18.

SELLAS Life Sciences Group (NASDAQ:SLS) last posted its quarterly earnings data on Wednesday, November 12th. The company reported ($0.06) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.08) by $0.02. Equities analysts forecast that SELLAS Life Sciences Group will post -0.57 EPS for the current year.

SELLAS Life Sciences Group Company Profile

SELLAS Life Sciences Group, Inc is a clinical-stage biopharmaceutical company focused on the development of active cellular immunotherapies for cancer. Headquartered in Waltham, Massachusetts, SELLAS specializes in targeting the Wilms’ tumor 1 (WT1) antigen, a protein commonly overexpressed in a range of hematologic and solid tumors. Since its founding, the company has built a pipeline around the use of peptide-based vaccines designed to train the patient’s own immune system to recognize and attack WT1-positive cancer cells.

The company’s lead product candidate, galinpepimut-S (GPS), is an investigational multi-peptide vaccine directed against WT1.